Targets › DPYD
4 programs from 4 companies in 5 trials: 3 Phase 2, 2 Phase 3; Oncology; next expected readout Dec 2026.
Catalyzes the reduction of uracil and thymine in the initial step of reductive pyrimidine catabolism, a pathway that yields beta-alanine from uracil and beta-aminoisobutyrate from thymine. Also capable of degrading the chemotherapeutic drug 5-fluorouracil. (UniProt, Q12882)
Open in Phaseline: the race on DPYD, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Kyungpook National University Hospital | FOLFOX-6 Combination chemotherapy: oxaliplatin (platinum agent), leucovorin (reduced folate), and 5 | DPYD, TYMS, DHFR | Phase 3 | Colon Cancer | Dec 2026 |
| National Cancer Center Hospital East | CAPOXIRI Combination chemotherapy: capecitabine (5-FU prodrug), oxaliplatin (platinum agent), and i | DPYD, TOPO1, XRCC1 | Phase 3 | Locally Advanced Rectal Cancer | Dec 2029 |
| Fudan University | mFOLFIRINOX plus IMRT Multi-drug chemotherapy regimen (5-fluorouracil, folinic acid, irinotecan, oxaliplatin) co | TOPO1, DPYD, TYMS, DHFR | Phase 2 | Pancreatic Adenocarcinoma; Pancreatic Cancer | Mar 2028 |
| Processa Pharmaceuticals | Eniluracil (PCS6422) Dihydropyrimidine dehydrogenase inhibitor | DPYD | Phase 2 | Breast Cancer | – |
Locally Advanced Rectal Cancer (1) Pancreatic Adenocarcinoma (1) Pancreatic Cancer (1) Colon Cancer (1) Breast Cancer (1)
small molecule (3)
National Cancer Center Hospital East (1) Fudan University (1) Kyungpook National University Hospital (1) Processa Pharmaceuticals (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.